Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Boeson Research LLC

Neither a doctor nor a teaching hospital

Research payments

$12,651,998

1,434 payments

Through program year 2025, Boeson Research LLC is reported as receiving $12,651,998 in research payments, across 1,434 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $2,977,999 312
2024 Research $3,102,146 248
2023 Research $2,914,934 302
2022 Research $1,938,997 287
2021 Research $1,478,398 252
2020 Research $239,524 33

Breakdown

Who paid Research payments · program years 2020–2025
  1. Moderna TX, Inc. $6,547,993 564 payments
  2. Pfizer Inc. $3,500,272 293 payments
  3. GlaxoSmithKline, LLC. $916,446 428 payments
  4. Eli Lilly and Company $645,545 8 payments
  5. Indivior Inc. $461,394 16 payments
  6. Sanofi US Services Inc. $177,169 33 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $139,658 27 payments
  8. Sanofi Pasteur Inc. $124,544 40 payments
  9. AbbVie, Inc. $80,599 20 payments
  10. AstraZeneca Pharmaceuticals LP $37,152 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $3,308,813 260 payments
  2. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $2,727,461 125 payments
  3. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $814,343 58 payments
  4. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $726,625 8 payments
  5. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $711,856 61 payments
  6. A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $461,394 16 payments
  7. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $423,434 28 payments
  8. Study name not reported $294,512 158 payments
  9. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity Or Overweight With and Without Type 2 Diabetes: J2a-Mc-Gzp1, J2a-Mc-Gzp2 $257,318 2 payments
  10. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers $255,821 103 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record